Form 4: Unity Biotechnology Director Acquires Stock Options

Camille D. Samuels, a director of Unity Biotechnology, acquired stock options for 10,000 shares of common stock on June 21, 2024.

Summary

• On June 21, 2024, Camille D. Samuels, a director of Unity Biotechnology, acquired stock options for 10,000 shares of common stock at an exercise price of $1.38.
• The options vest on the earlier of June 21, 2025, or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director.
• Samuels is a member of VR Management, LLC, and holds the options for the benefit of the Management Company.
• VR Management, LLC directs the exercise of the options and is entitled to the underlying shares.
• Samuels disclaims beneficial ownership of the reported shares except to the extent of her pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects a routine transaction and doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC when insiders, such as directors and officers, transact in their company's stock; this filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Key Dates